SY

Steven Yatomi-Clarke

Prescient Therapeutics Limited | Chief Executive Officer, Managing Director
Mr Yatomi-Clarke manages a team in Australia and the US and has been involved in strategy development, licensing; initiating and managing clinical trials; identifying research directions and pre-clinical research design; fundraising and business development. He has over 17 years of experience in investment banking specializing in healthcare and biotechnology, where he was consistently one of the most prolific and successful bankers, involved in primary and secondary offerings, corporate advisory and mergers and acquisitions assignments for pharmaceutical and medical device companies.

Company and Roles

Company
Title
Tenure
Since
PTX
Prescient Therapeutics Limited
  • Chief Executive Officer
  • Managing Director
9yrs, 5mthNov 2014

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
PTX
Prescient Therapeutics Limited
30/06/235,790,6475,404,37012,900,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
PTX
Prescient Therapeutics Limited
01/05/23
Issued
1,148,936$0.098$112,595Exercise of options
PTX
Prescient Therapeutics Limited
01/05/23
Exercise
2,351,064$0.098$230,404Exercise of options
PTX
Prescient Therapeutics Limited
04/04/23
Exercise
97,692$0.062$6,105Exercise of options
PTX
Prescient Therapeutics Limited
04/04/23
Buy
97,692$0.062$6,105Exercise of options
PTX
Prescient Therapeutics Limited
14/12/22
Issued
641,711$0.135$86,630Exercise of options